In viable parenchymal neurocysticercosis, the co-occurrence of increased intracranial pressure — driven by untreated hydrocephalus or diffuse cerebral edema — defines a distinct management scenario where standard antiparasitic therapy does not apply.
Viable parenchymal neurocysticercosis with untreated hydrocephalus or diffuse cerebral edema and elevated intracranial pressure. Both conditions raise ICP through different mechanisms, and each requires a specific management path before any antiparasitic therapy can be considered.
The primary goal is control of elevated intracranial pressure, not antiparasitic therapy. The intervention type differs depending on whether the ICP elevation originates from diffuse cerebral edema or from hydrocephalus — one presentation is addressed with anti-inflammatory therapy, while the other typically calls for a surgical approach. The complete regimen, criteria, and sequencing are available in the full structured protocol.
DOI: 10.1093/cid/cix1084
In patients with untreated hydrocephalus or diffuse cerebral edema, we recommend management of elevated intracranial pressure alone and not antiparasitic treatment (strong, moderate).
Antiparasitic drugs can worsen cerebral edema and should generally be avoided in patients with increased intracranial pressure from either diffuse cerebral edema (cysticercal encephalitis) or untreated hydrocephalus.
The management of patients with diffuse cerebral edema should be anti-inflammatory therapy such as corticosteroids, whereas hydrocephalus usually requires a surgical approach.
View source ↗